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TO THE EDITOR
Among the millions of people who
develop a ﬁrst basal cell carcinoma
(BCC) annually, ~30% will get subse-
quent BCCs (Flohil et al., 2013). The
majority of BCCs occur on the head
and neck, where tumor growth and
surgery can lead to functional and cos-
metic morbidity. Because of the high
incidence, risk of multiple tumors, and
morbidity, the disease burden and health-
care costs are considerable (Housman
et al., 2003; Hollestein et al., 2014).
Several candidate gene approaches
(CGAs) suggest that polymorphisms in
the genes encoding cytochrome P450,
glutathione S-transferase, and HLA are
implicated in the development of multi-
ple BCCs (mBCC; Cerimele et al., 1988;
Rompel et al., 1995; Lear et al., 1996;
Ramachandran et al., 2000). Most of
these studies have a small sample
size and include only a few variants
per gene. To date, there are no
studies investigating whether more
recently identiﬁed BCC loci also confer
susceptibility to mBCC. We investigated
whether single-nucleotide polymorph-
isms (SNPs) previously associated with
BCC increase the risk of mBCC using a
CGA. In addition, we conducted a
genome-wide association study (GWAS)
to identify previously unreported loci
associated with the risk of mBCC.
A detailed description of all the
methods is presented in the Supple-
mentary Material online. We used
participants from the Rotterdam Study
(RS), which is a population-based
follow-up study that consists of three
cohorts (RS-I, II, and III; Hofman et al.,
2013). The Medical Ethics Committee of
the Erasmus Medical Center and the
review board of the Dutch Ministry of
Health, Welfare and Sport have ratiﬁed
the RS. All participants who gave
informed consent were linked with a
nationwide registry of histopathology in
The Netherlands (PALGA, up to 31
December 2013) to identify histopatho-
logically conﬁrmed BCCs, squamous
cell carcinomas (SCCs), and melano-
mas (Casparie et al., 2007).
DNA from whole blood was
extracted and genotyped following stan-
dard protocols (Hofman et al., 2013).
Quality control procedures were
applied to the genotyped SNP data.
The GWA data sets were imputed to the
1,000 Genomes data set using MACH-
minimac v1.0.18 (Howie et al., 2012).
In total, 30,072,738 markers were geno-
typed and/or imputed. We excluded
markers with a minor allele frequency
o3% and an imputation quality o0.3.
After quality control, 7,260,691 markers
were available for analysis.
From the 9,810 RS participants with
genotype and phenotype information,
1,219 individuals with BCC were iden-
tiﬁed, of whom 472 had mBCC (38.7%).
Participants with mBCC had a signiﬁ-
cantly higher proportion of SCCs and/or
melanomas compared with those with
single BCC (sBCC; Supplementary Table
S1 online).
First, 19 candidate SNPs and 17 loci
from well-powered GWASs/CGA of
BCC were selected (Supplementary
Table S2 and Supplementary Material
online). We then conducted SNP- and
gene-based logistic regression analyses
in two data sets, comparing BCC to no
BCC (i.e., validation set) and mBCC to
sBCC to investigate whether these BCC
loci also increase the risk of mBCC. The
analyses were adjusted for age at study
entry or age at ﬁrst BCC, sex, and
four principal components (PCs). As
these SNPs and loci were previously
signiﬁcantly associated with BCC, we
only adjusted for multiple testing in the
mBCC versus sBCC data set using the
Bonferroni correction. All analyses were
performed in PLINK v1.07 (Purcell
et al., 2007).
In the CGA on BCC against no BCC,
12/19 (63%) candidate SNPs and 5/17
(29%) loci were replicated, demonstrat-
ing a good external validity of the study
(Table 1 and Supplementary Table S3A
online). Interestingly, the CGA compar-
ing sBCC to mBCC did not yield
any signiﬁcant associations between
these BCC-related SNPs/loci and risk
of mBCC (Table 1 and Supplementary
Table S3B online).
Finally, we conducted a pilot GWAS
using logistic regression (additive
model) to test for associations between
markers and mBCC, adjusting for age at
diagnosis, sex, and four PCs (Supple-
mentary Material online). A meta-
analysis of the GWAS results per cohort
was performed. Despite the low overall
power to detect genome-wide signiﬁ-
cant hits (Supplementary Figure S1
online), we identiﬁed genome-wide
suggestive associations in chromosomes
2, 3, 18, and 22 (P-values o5× 10−6,
Supplementary Figure S2 online and
Table 2). The most signiﬁcant SNP was
rs78857623 (P-value=1.2×10−7,
Table 2), which mapped to an intron
in FHIT, and it was in linkage disequili-
brium (r2=0.65) with another signiﬁ-
cantly associated intronic FHIT SNP
(rs78316259; P-value= 4.6× 10− 6).
FHIT is a tumor suppressor gene that
encodes a diadenosine polyphosphate
hydrolase involved in purine metabo-
lism (Barnes et al., 1996). Aberrant FHIT
transcripts as well as germline muta-
tions in this gene have been found in
different cancers including BCC (Ohta
et al., 1996; Goldberg et al., 2006; Ding
et al., 2008).
Given the high proportion of SCCs
and melanomas in mBCC cases, a; ;Accepted article preview online 24 March 2015; published online 23 April 2015
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JAC Verkouteren et al.
Common Variants for Multiple Basal Cell Carcinomas
www.jidonline.org 2135
sensitivity analysis investigating the
inﬂuence of other cutaneous cancers
was performed (Supplementary Table
S1 online). We observed changes in the
P-values of the associations due to a
13% decrease in sample size, but all
top SNPs remained signiﬁcant with a
P-valueo5×10− 5 (data not shown),
showing that our ﬁndings were driven
by BCC cases.
In contrast to other BCC GWASs, we
performed a GWAS on histopathologi-
cally conﬁrmed mBCC. By combining
national pathology data with genome-
wide SNP data from a population-based
study, we accurately distinguished
between sBCC and mBCC. It is a
pilot GWAS because the sample size
is small and replication data are not
easily available. All existing cohorts,
which have performed genetic epide-
miology on skin cancer, do not have
data on mBCC. Like in other
GWASs, the signiﬁcant associations
are only statistical and therefore any
inference about the functional impact of
the variants to the risk of mBCC needs to
be investigated with other approaches.
Despite these limitations, our data set
contains the largest collection of cases
with mBCC to date and may serve as a
valuable reference for future studies.
Because of the high risk of subse-
quent BCCs in individuals with a ﬁrst
BCC, we expected that loci predispos-
ing to sBCCs would also contribute to
the risk of mBCC. However, the CGA
analysis did not support this hypo-
thesis, suggesting that other biological
factors, including genes, may confer an
increased risk to mBCC. The earlier
onset of ﬁrst BCCs in patients
with mBCC may indeed suggest that
these patients have a stronger genetic
burden compared with those with sBCC
(68.7 vs. 72.4 years; P-value o0.05,
Supplementary Table S1 online). A
heritability analysis comparing mBCC
against sBCC in well-powered samples
will help validate this hypothesis. It
could also be argued that other yet-to-
be-identiﬁed loci conferring suscep-
tibility to BCC may also increase risk
of mBCC, which will require larger
consortia on the genetics of BCC.
In conclusion, genetic loci previously
associated with BCC do not increase the
risk of mBCC. A pilot GWAS on mBCC
identiﬁed to our knowledge previously
unreported susceptibility variants, but
these ﬁndings need to be replicated in
other mBCC cohorts.
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Table 1. SNP-based and gene-based association analyses
SNP Locus
BCC versus no BCC mBCC versus sBCC
SNP-based P-value Gene-based P-value SNP-based OR SNP-based P-value Gene-based P-value SNP-based OR
rs1126809 TYR 0.0027 0.14 1.16 0.99 0.16 1.0010
rs4911414 20q11.22 0.067 0.96 1.086 0.49 0.77 0.94
rs1015362 20q11.22 0.83 0.96 1.010 0.15 0.77 0.87
rs7538876 PADI6 0.00062 0.075 1.16 0.063 0.11 1.17
rs801114 1q42.13 0.0070 0.049 1.13 0.63 0.75 0.96
rs11170164 KRT5 0.17 0.0020 1.12 0.13 0.24 1.27
rs2151280 CDKN2B-AS1 0.0043 0.13 0.88 0.97 0.64 1.00
rs157935 LINC-PINT 0.00077 0.10 0.85 0.18 0.86 0.88
rs16891982 SLC45A2 0.0081 0.038 0.65 0.82 0.47 0.93
rs401681 CLPTM1L 0.00053 0.022 0.86 0.36 0.83 0.92
rs12210050 EXOC2 0.030 0.35 1.15 0.69 0.13 0.95
rs7335046 UBAC2 0.19 0.35 1.087 0.10 0.016 1.22
rs1805007 MC1R 0.069 0.60 1.16 0.43 0.25 0.88
rs78378222 TP53 0.037 0.17 1.34 0.13 0.39 1.49
rs12203592 IRF4 7.7E–05 0.063 1.31 0.35 0.30 0.89
rs12202284 EXOC2 0.12 0.35 1.096 0.88 0.13 1.017
rs8015138 14q22.1 0.79 0.088 0.99 0.91 0.72 0.99
rs214782 TGM3 1.2E–05 0.0070 1.27 0.056 0.19 1.22
rs7006527 RGS22 0.0018 0.17 0.82 0.49 0.85 1.088
Abbreviations: BCC, basal cell carcinoma; mBCC, multiple basal cell carcinomas; OR, odds ratio; sBCC, single basal cell carcinoma; SNP, single-nucleotide
polymorphism.
Numbers in bold display signiﬁcant differences (P-value o0.05). The gene-based P-value for mBCC versus sBCC should be corrected for multiple testing.
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TO THE EDITOR
Basal cell carcinomas (BCCs) are locally
invasive epithelial tumors that are
caused by activating mutations in the
Hedgehog (HH) pathway, typically
through the loss of the receptor Patched1
or by activating the G-protein-coupled
receptor Smoothened (SMO). Genomic
analysis by our group and others have
revealed that BCCs are typically diploid
and carry a high frequency of non-silent
single-nucleotide variants (SNVs) com-
pared with other cutaneous and non-
cutaneous tumors (Alexandrov et al.,
2013; Atwood et al., 2014; Jayaraman
et al., 2014; Atwood et al., 2015). Given
their high mutational load, how these
variants confer selective tumor growth
without deleterious effects remains
poorly understood. We previously
identiﬁed and functionally validated
nine SMO mutations that drive the
majority of drug resistance in BCC thro-
ugh two distinct mechanisms that
maintain HH signaling in the presence
of drug: induction of constitutive activity
and disruption of ligand binding
(Atwood et al., 2015). However, SMO
mutations with unclear function are
frequently found across many HH
and non-HH-dependent cancers, with
drug-resistant BCCs bearing the highest
rate of recurrent mutations at 66%
(Figure 1a).
To determine how these additional
SMO mutations promote tumor growth,
we identiﬁed 28 mutations through our
genomic analysis of 44 drug-resistant
and 36 sporadic BCCs that were either
recurrent, found to overlap with the
COSMIC database, or were region-
speciﬁc (ligand-binding pocket or pivot
region) and interrogated their ability to
promote HH signaling (Figure 1b, c).
We expressed wild-type human SMO
(SMO-WT) or SMO mutants in Smo-null
mouse embryonic ﬁbroblasts (MEFs) to
assess the ability of these variants to
activate the HH pathway with or with-
out ligand (Supplementary Materials
online). SMO-W535L is a known con-
stitutively active mutant that was pre-
sent in many of our tumor samples and
signiﬁcantly increased basal HH activity
in the absence of HH ligand as deter-
mined by mRNA levels of the HH target
gene Gli1 (Figure 2a). No other SMO
variant induced constitutive activity,
including SMO-WT and the known
ligand-binding pocket mutant SMO-
D473G (Yauch et al., 2009), suggest-
ing that these variants could not confer
tumor growth by themselves. This was
surprising, as several of the residues
(A327P, T336I, V414A, and T534I) lie
in the pivot regions of transmembrane
helices 3, 5, and 7, which control SMO
activation (Figure 1c) and correspond to
residues 320–340, 410–415, and 530–
540 from the SMO crystal structure
(Wang et al., 2013; Atwood et al.,
2015). Addition of HH ligand revealed
a range of responses from the SMO
variants to activate the pathway. No
SMO mutation conferred a statistically
signiﬁcant increase in SMO activity,
with the majority of variants acting as
passenger mutations (Figure 2b). How-
ever, 13 variants disrupted SMO activity
by 50% or more, with 7 of the variants
effectively abolishing activity. How the
tumor could withstand the loss of SMO
activity remains unclear, although only
one functional copy of SMO is neces-
sary to transduce the HH signal.
To assess the ability of the SMO
variants to confer drug resistance to
vismodegib, the current FDA-approved
SMO antagonist, we added both HH
ligand and 100 nM vismodegib to the
Smo-null MEFs and assayed for HH
activation. SMO-D473G and SMO-
W535L both resisted SMO inhibition
and displayed robust activation as
expected (Figure 2c). However, no
other SMO variant conferred vismode-
gib resistance, suggesting that these
mutations could not confer drug resis-
tance and that the resistance mechan-
ism in these tumors would be
independent of SMO. This is also
surprising as seven of these variants; ;Accepted article preview online 24 March 2015; published online 14 May 2015
Abbreviations: BCC, basal cell carcinoma; HH, Hedgehog; MEF, mouse embryonic ﬁbroblast; SMO,
Smoothened; SNV, single-nucleotide variant; WT, wild type
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